Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Given Average Recommendation of “Buy” by Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWLGet Rating) have received an average rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $26.20.

Separately, Zacks Investment Research raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its holdings in Werewolf Therapeutics by 245.0% in the fourth quarter. BlackRock Inc. now owns 1,276,208 shares of the company’s stock worth $15,200,000 after purchasing an additional 906,247 shares in the last quarter. Wells Fargo & Company MN acquired a new position in shares of Werewolf Therapeutics during the fourth quarter valued at about $151,000. Goldman Sachs Group Inc. acquired a new position in shares of Werewolf Therapeutics during the fourth quarter valued at about $120,000. The Manufacturers Life Insurance Company acquired a new position in shares of Werewolf Therapeutics during the fourth quarter valued at about $153,000. Finally, Deutsche Bank AG increased its holdings in shares of Werewolf Therapeutics by 268.8% during the fourth quarter. Deutsche Bank AG now owns 16,047 shares of the company’s stock valued at $191,000 after acquiring an additional 11,696 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

HOWL stock opened at $4.37 on Friday. The firm has a fifty day moving average price of $5.22 and a 200 day moving average price of $10.21. Werewolf Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $23.99. The firm has a market cap of $120.85 million and a PE ratio of -0.05.

Werewolf Therapeutics (NASDAQ:HOWLGet Rating) last posted its quarterly earnings data on Thursday, March 24th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.13). As a group, research analysts anticipate that Werewolf Therapeutics will post -2.43 EPS for the current fiscal year.

About Werewolf Therapeutics (Get Rating)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

Featured Articles

Analyst Recommendations for Werewolf Therapeutics (NASDAQ:HOWL)

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.